Factual data · GO/NO-GO verdict · Financial model calibrated over 96 months
A pharmacy in Nice generates 1.7M €-5.2M € € revenue, with net margin of 8 %. Typical mix: 75-85 % prescription drugs (regulated margin), 15-25 % OTC/wellness (free margin 35-45 %).
Dominant profile: touristique · balneaire · residentielle
Competitive density: high (dense supply, segmentation required).
Dominant players: regulated public-insurance sector, few private chains.
Positioning recommendation: Competitive positioning required: sector margin is tight, edge comes from operational efficiency.
| Indicator | Year 1 | Year 2 | Year 3 |
|---|---|---|---|
| Year 1 revenue | 1.7M € → 5.2M € | ×1,18 (ramp-up) | ×1,32 (steady-state) |
| Target net margin | negative to low | 4 % | 10 % |
| Working capital (days of revenue) | 45-60 d | 35-50 d | 30-45 d |
| Cumulative ROI | investment | ~50 % | Payback at 96 months |
These ratios are calibrated on MarketLens sector benchmarks and adjusted by local coefficients of Nice (cost +25% vs average, income +15% vs average).
MarketLens combines AI market study, business plan calibrated for 24 countries, and post-launch monitoring. Everything exportable to PDF, PowerPoint, Excel and Word.